Vedanta thinks its live biotherapeutic sourced from clonal cell banking could offer strong prevention against C. difficile infections after antibiotics have cleared an initial infection.

What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.

Korean bioventure Genome & Co. is accelerating growth by acquiring US microbiome CDMO List Labs, following on from its purchase of US microbiome therapeutics firm Scioto last year. With its microbiome pipeline reaching milestones as planned, Genome appears on track for its goal of becoming a fully integrated global biopharma concern.

In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.